Recall alert: Orajel teething swabs pulled from shelves over potential fungal contamination
Orajel teething swabs recalled over fungal concerns—here's what parents should know
If you have a stash of teething remedies tucked into your medicine cabinet, it may be time to take a second look. Church & Dwight Co., Inc. has issued a voluntary nationwide recall of several swab-based products—including certain Orajel Baby Teething Swabs—due to possible fungal contamination in the cotton tip component.
The recall also includes two types of Zicam nasal swabs. According to the FDA's official alert, these fungi could pose a health risk, especially for children or individuals with weakened immune systems.
This isn't a reason to panic—but it is a moment to pause and take action.
Related: 1.7 million eggs recalled across 9 states after salmonella outbreak
All lot numbers of the following products are affected:
Orajel Baby Teething Swabs UPC: 310310400002Use: To soothe teething discomfort in babies and toddlers
Zicam Cold Remedy Nasal Swabs UPC: 732216301205Use: Homeopathic swab meant to shorten cold duration
Zicam Nasal AllClear Swabs UPC: 732216301656Use: Nasal cleansing swabs (discontinued in 2024)
Important: This recall does not include other Orajel or Zicam products, such as gels or RapidMelts.
Check your medicine cabinet for any of the products above. Look for the UPC code on the packaging.
Stop using recalled products immediately.
Visit www.churchdwightrecall.com or call 1‑800‑981‑4710 (Mon–Fri, 9 a.m.–5 p.m. ET) for a full refund.
Dispose of the product safely—do not donate or give it away.
Related: Check your fridge: Cucumber recall hits 15 states after salmonella outbreak
The FDA says the risk is highest for individuals with inflamed nasal tissue or weakened immune systems, as the fungal contamination could lead to serious infections, especially in the bloodstream.
But if your baby seems healthy and has shown no unusual symptoms, there's no immediate cause for alarm.
Still, if you've recently used a recalled swab call your pediatrician and mention the recall for guidance.
Recalls like these are unsettling—but they're also a sign that safety systems are working. If you've used these products, take a breath. Take the next step. You're doing the right thing by staying informed and responsive.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Insider
2 hours ago
- Business Insider
Capricor treatment of Becker muscular dystrophy granted orphan designation
The FDA granted orphan designation to a treatment of Becker muscular dystrophy being developed by Capricor, according to a post to the agency's website. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Yahoo
3 hours ago
- Yahoo
Insmed Inc (INSM) Soars 30% on Impressive Study
We recently published a list of . In this article, we are going to take a look at where Insmed Incorporated (NASDAQ:INSM) stands against other top-performing companies on Tuesday. Insmed Inc. soared by 28.65 percent on Tuesday to close at $90.93 apiece following positive results from the phase 2 trial of its pulmonary arterial hypertension (PAH) treatment, treprostinil palmitil inhalation powder (TPIP). Insmed Incorporated (NASDAQ:INSM) jumped as high as 30 percent at intraday trading following the announcement. According to the company, the phase 2 trial achieved its primary and secondary goals for the treatment of reducing blood pressure in the lungs and improving exercise capacity in patients. Following the results, Insmed Incorporated (NASDAQ:INSM) said it would engage with the Food and Drug Administration (FDA) regarding the phase 3 trial design. The company said it plans to initiate a Phase 3 trial in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) before the end of the year, to be followed by a Phase 3 trial in patients in early 2026. A biopharmaceutical research team taking notes in front of a laboratory's microscope. 'These unprecedented Phase 2b results unequivocally demonstrate TPIP's potential to be a highly effective and well-tolerated once-daily prostanoid therapy for the treatment of PAH across disease severities and background treatment regimens. We look forward to expanding upon these results in the upcoming Phase 3 program,' the company said. Overall, INSM ranks 1st on our list of top-performing companies on Tuesday. While we acknowledge the potential of INSM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Insider
4 hours ago
- Business Insider
KalVista says FDA will not meet PDUFA goal date for Sebetralstat NDA
KalVista (KALV) Pharmaceuticals nnounced that the U.S. Food and Drug Administration has notified the company that it will not meet the PDUFA goal date for the New Drug Application for sebetralstat, the company's investigational oral on-demand treatment for hereditary angioedema. The FDA notified the company on June 13, 2025, that the previously disclosed June 17, 2025 PDUFA goal date will not be met due to heavy workload and limited resources. The FDA indicated that it expects to deliver a decision within approximately four weeks. The FDA has not requested additional data or studies and has not raised any concerns regarding the safety, efficacy or approvability of sebetralstat. KalVista has addressed all prior information requests in a timely manner, and the company believes the only remaining item under FDA review is the finalization of the labelling. 'We are disappointed by this delay, most importantly because we know how much people living with HAE are looking forward to an oral on-demand option to treat their HAE attacks,' said Ben Palleiko, CEO of KalVista. 'At the same time, we remain confident in the near-term approval of sebetralstat. We are continuing to work closely with the FDA to support the completion of their review. Our commitment to bringing this important therapy to people living with HAE remains unwavering.'